Medline Expanding Clinician Access to Products Designed to Safely Control Bleeding
Distribution agreement with Tricol Biomedical aims to increase portfolio reach across North America
News provided by
Share this article
Share this article
NORTHFIELD, Ill., Jan. 6, 2021 /PRNewswire/ Medline and Tricol Biomedical, Inc. today announced an exclusive agreement to distribute Hemostatic Control (HemCon) products in North America to acute care, emergency services, and cath lab providers.
Severe bleeding accounts for over 35% of pre-hospital deaths and close to 40% of deaths within the first 24 hours of sustaining an injury, according to a 2015 National Trauma Institute estimate.
Rapid control of bleeding can be applied across specialties within the continuum of care, from Trauma to Cardiology to Home Health. Managing blood loss within a healthcare facility can prevent unnecessary deaths in severe cases or improve a patient s care experience during vascular access procedures or r